Nortunen Minna, Meriläinen Sanna, Ylimartimo Aura, Peroja Pekka, Karjula Heikki, Niemelä Jarmo, Saarela Arto, Huhta Heikki
Department of Surgery, Anesthesia and Intensive Care Research Unit, Oulu University Hospital, Oulu, Finland.
J Gastrointest Oncol. 2023 Feb 28;14(1):366-378. doi: 10.21037/jgo-22-649. Epub 2023 Feb 24.
Short-term outcomes of pancreatic surgery have improved globally during the last two decades. Long-term survival of resectable pancreatic ductal adenocarcinoma (PDAC) has also shown slight improvement. We describe a cohort of 566 consecutive pancreatectomies performed at a Northern Finnish tertiary center. We analyze the trends in short-term outcomes of all-cause pancreatic surgery and long-term survival of PDAC patients.
All pancreatic resections performed at the Oulu University Hospital during years 2000-2020 were included. Patient data was analyzed in four time periods (2000-2005, 2006-2010, 2011-2015 and 2016-2020). Clinicopathological parameters of patients and tumors, complication data and short-term mortality were recorded for all patients and compared between time quartiles. Long-term survival and administration rates of neo-, and/or adjuvant therapy of PDAC patients were analyzed.
A total of 566 pancreatectomies were performed during the study period: 359 (63%) pancreatoduodenectomies (PDs), 130 (23.0%) open left pancreatectomies (LPs), 45 (8.0%) laparoscopic LPs, 26 (5.1%) total pancreatectomies (TPs), and 6 (1.1%) enucleations. Median age of patients was 63 [57-71] years, and 49% [267] of patients were men. Number of pancreatectomies per time period increased from 67 in 2000-2005 to 266 in 2016-2020. American Society of Anesthesiologists (ASA) Physical Classification III patients and T3 tumors were more frequently operated on in later time periods. Complication rates remained at constant low levels throughout the study period, but reoperation rate increased from 9.4% in 2000-2010 to 16.2% in 2011-2020. Short-term (90-day) mortality after pancreatectomy decreased from 3.1% to 0.74%, while 5-year survival improved from 14.3% in 2006-2011 to 21.4% in 2011-2015. Resection rate of diagnosed PDAC cases, as reported by the Finnish Cancer Registry (FCR) for the catchment area, increased from 3.2% to 14.9% over the study period.
The hospital volume of pancreatectomies has increased substantially, while complications and postoperative mortality have remained at acceptable levels. Long-term survival and resection rate of PDAC patients showed notable improvement over two decades.
在过去二十年中,全球范围内胰腺手术的短期疗效有所改善。可切除性胰腺导管腺癌(PDAC)的长期生存率也略有提高。我们描述了芬兰北部一家三级中心连续进行的566例胰腺切除术。我们分析了全因胰腺手术短期疗效及PDAC患者长期生存的趋势。
纳入2000年至2020年在奥卢大学医院进行的所有胰腺切除术。患者数据按四个时间段(2000 - 2005年、2006 - 2010年、2011 - 2015年和2016 - 2020年)进行分析。记录所有患者的患者及肿瘤的临床病理参数、并发症数据和短期死亡率,并在四个时间四分位数之间进行比较。分析PDAC患者的长期生存情况以及新辅助和/或辅助治疗的应用率。
研究期间共进行了566例胰腺切除术:359例(63%)胰十二指肠切除术(PD),130例(23.0%)开放性左胰腺切除术(LP),45例(8.0%)腹腔镜LP,26例(5.1%)全胰腺切除术(TP),6例(1.1%)肿瘤剜除术。患者的中位年龄为63岁[57 - 71],49%[267例]为男性。每个时间段的胰腺切除例数从2000 - 2005年的67例增加到2016 - 2020年的266例。美国麻醉医师协会(ASA)身体状况分级III级的患者和T3期肿瘤患者在后期时间段接受手术的频率更高。在整个研究期间,并发症发生率保持在较低水平,但再次手术率从2000 - 2010年的9.4%增加到2011 - 2020年的16.2%。胰腺切除术后的短期(90天)死亡率从3.1%降至0.74%,而5年生存率从2006 - 2011年的14.3%提高到2011 - 2015年的21.4%。芬兰癌症登记处(FCR)报告的研究区域内确诊PDAC病例的切除率在研究期间从3.2%提高到14.9%。
胰腺切除术的医院手术量大幅增加,而并发症和术后死亡率保持在可接受水平。PDAC患者的长期生存率和切除率在二十年间有显著提高。